What GHRP-6 is

GHRP-6 belongs to the growth-hormone-axis family of research peptides. The family divides cleanly into two mechanistic groups: GHRH analogues (Sermorelin, CJC-1295, Tesamorelin, Mod-GRF 1-29) that bind the GHRH receptor on somatotroph cells in the anterior pituitary, and GHRPs / ghrelin-mimetics (Ipamorelin, GHRP-2, GHRP-6, MK-677/Ibutamoren, Hexarelin) that bind the growth hormone secretagogue receptor (GHSR-1a). Combining one from each group synergistically amplifies pulsatile GH release above what either produces alone.

Mechanism of action

• GHRH analogues stimulate GH release via cAMP-dependent signaling in somatotrophs. They preserve the natural pulsatile pattern of GH secretion — a mechanistic advantage over exogenous rhGH.
• GHRPs / ghrelin-mimetics bind GHSR-1a, causing calcium-dependent GH release and simultaneously suppressing somatostatin (the negative regulator of GH). Ipamorelin is notable for GH-selectivity — it releases GH with minimal effect on cortisol, prolactin, or ACTH, which is why it appears frequently in the literature.

Downstream, GH drives hepatic IGF-1 production. Most of the anabolic and regenerative endpoints attributed to this class are IGF-1-mediated rather than direct effects of GH itself.

Published research findings

• Tesamorelin is FDA-approved for HIV-associated lipodystrophy; multiple published trials show reduction in visceral adipose tissue.
• Sermorelin was FDA-approved for pediatric GH-deficiency (later discontinued for commercial reasons, not safety).
• Ipamorelin and CJC-1295 are extensively studied in animal models of GH insufficiency and in academic pharmacokinetic studies.
• MK-677 (Ibutamoren) is an orally-bioavailable non-peptide ghrelin mimetic with published human PK data.

Dosing ranges reported in the literature

Doses reported in academic and industry protocols, provided as reference only:

• Sermorelin: 200–500 µg subcutaneous nightly.
• CJC-1295 (no DAC / Mod-GRF 1-29): 100 µg subcutaneous, up to three times daily around meals and pre-sleep.
• CJC-1295 with DAC: 1–2 mg subcutaneous weekly; DAC extends half-life through albumin binding.
• Ipamorelin: 100–300 µg subcutaneous, 1–3 times daily.
• Tesamorelin: 1–2 mg subcutaneous nightly.
• MK-677: 10–25 mg orally, once daily.

Timing in the literature emphasizes fasting-state administration — GH release is blunted by concurrent hyperglycemia and hyperinsulinemia, so protocols typically dose pre-sleep and inter-meal.

Stacking discussed in the literature

• CJC-1295 + Ipamorelin — the canonical GHRH + GHRP stack for pulsatile GH amplification.
• Sermorelin + Ipamorelin — similar pairing with a shorter-acting GHRH.
• Tesamorelin + Ipamorelin — for research protocols targeting visceral fat.

Considerations and reported effects

Water retention, transient injection-site erythema, and (with higher-dose GHRPs) hunger driven by GHSR-1a agonism are the most commonly-reported effects. Ipamorelin's cortisol/prolactin selectivity is why it appears more often than GHRP-2 or GHRP-6 in modern protocols.

Standard laboratory handling

Every research vial from PX1 is a lyophilized (freeze-dried) powder sealed under vacuum in a Type-I borosilicate vial with a butyl-rubber stopper and aluminum crimp seal. Correct handling preserves potency and prevents peptide-bond hydrolysis that degrades the active molecule.

• Storage before reconstitution: 2–8 °C refrigerator is ideal; freezer (−20 °C) for storage beyond six months. Short excursions to room temperature during shipping do not compromise integrity — the compound is stable in its solid state.
• Reconstitution solvent: bacteriostatic water for injection (0.9% benzyl alcohol) is standard for research protocols that require multiple sampling events from the same vial. Sterile water is acceptable for single-use protocols.
• Reconstitution technique: inject the diluent slowly against the vial wall — never directly onto the lyophilized cake. Swirl gently; do not shake. Shaking introduces air, denatures peptide secondary structure, and can create insoluble aggregates.
• Post-reconstitution storage: 2–8 °C refrigerated, typically stable 21–30 days depending on the peptide. Freezing a reconstituted solution repeatedly is not recommended — freeze/thaw cycles are the single biggest driver of loss-of-potency in the research literature.
• Concentration math: volume of diluent (mL) = peptide mass (mg) ÷ desired concentration (mg/mL). Example: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL.

Purity, identity and COA verification

The single most important due-diligence step when sourcing GHRP-6 for research is reviewing the lot-specific Certificate of Analysis (COA). A credible COA contains:

1. HPLC purity value with chromatogram — target ≥ 98% for injectable-grade research peptides; ≥ 99% for the newest generation of GLP/incretin compounds. A single well-defined main peak with baseline separation from impurities is what you are looking for.
2. Identity confirmation by mass spectrometry — LC-MS or MALDI-TOF confirming the observed molecular weight matches the theoretical mass to within instrument tolerance.
3. Endotoxin (LAL / kinetic-chromogenic) result — expressed in EU/mg; USP guidance for parenteral products is well below 5 EU/kg body-weight equivalent, and reputable suppliers report < 10 EU/mg on the COA.
4. Sterility result — USP <71> membrane filtration or direct inoculation, both bacterial and fungal.
5. Karl Fischer moisture — target < 5% residual water for a properly lyophilized cake.
6. Residual-solvent screen — DMF, TFA, DCM, acetonitrile below ICH Q3C thresholds.

PX1 publishes lot-specific COAs at /purity-reports. If you have received a shipment and want to verify the exact lot documentation for GHRP-6, cross-reference the lot number on the vial label to the COA PDF.

Why researchers choose PX1 for GHRP-6

• 100% U.S. synthesis, lyophilization, and fill/finish. No repackaged imports. Every step from raw amino acid to sealed vial happens under one U.S. GMP-compliant roof.
• Third-party ISO-17025 testing on every lot. Purity, identity, endotoxin, sterility, moisture, and residual-solvent testing performed by an independent analytical laboratory whose data appears on the shipped COA.
• Chain-of-custody documentation from raw material through final QC — the same documentation package a clinical CDMO would provide.
• Same-day shipping on in-stock catalog items ordered before 3 p.m. ET, with insulated packaging and cold-pack where appropriate.

Common researcher questions

Q: How do I know the vial contents match the label? Compare the lot number on the vial to the lot number on the COA. The COA lists HPLC purity, identity by mass-spec, and endotoxin. If any of the three is missing or the lot doesn't match, don't proceed.

Q: Can I use bacteriostatic water past its printed expiration? Bacteriostatic water carries a manufacturer-assigned expiration for the sealed vial. Once punctured, USP guidance limits multi-dose vials to 28 days at 2–8 °C. Beyond 28 days, discard.

Q: Is refrigeration required during shipping? For most lyophilized peptides, no — the solid form is stable at ambient temperature for weeks. Some compounds (IGF-1 LR3, certain GH-releasing peptides) benefit from cold-chain shipping. PX1 uses insulated packaging for temperature-sensitive lines.

Q: What if the reconstituted solution is cloudy? Cloudiness indicates aggregation or precipitation and the solution should not be used. Common causes: over-vigorous shaking, incompatible diluent, or a vial that has passed its stability window.

Research use disclaimer

GHRP-6 is supplied to licensed research professionals for in vitro and in vivo laboratory research only. Products are not intended for human consumption, veterinary use, diagnostic use, therapeutic use, or as a food additive or cosmetic. Nothing on this page constitutes medical advice. Consult the primary literature — clinical-trial registrations, peer-reviewed publications — before designing any protocol. Compounds discussed here are investigational; several have not received FDA approval for any indication.

Additional PX1 references

• Complete research library
• Lot-specific purity reports
• Product catalog
• Manufacturing & QC standards